Retrospective Evaluation of Lung Adenocarcinoma Patients Progressing on 1st Line Chemotherapy
<i>Background and Objectives:</i> Evaluation of data from electronic health care records could help in guiding towards more rational drug treatments. This single center study evaluated clinical characteristics that could be associated with disease progression. <i>Methods:</i>...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-11-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1010-660X/55/11/743 |
| _version_ | 1797707561032482816 |
|---|---|
| author | Heikki Vilhonen Samu Kurki Tarja Laitinen Samuli Hirsjärvi |
| author_facet | Heikki Vilhonen Samu Kurki Tarja Laitinen Samuli Hirsjärvi |
| author_sort | Heikki Vilhonen |
| collection | DOAJ |
| description | <i>Background and Objectives:</i> Evaluation of data from electronic health care records could help in guiding towards more rational drug treatments. This single center study evaluated clinical characteristics that could be associated with disease progression. <i>Methods:</i> This was a real world data (RWD) study using existing data from the registries of a university hospital. Patients had lung adenocarcinoma and they had received 1st line treatment. Treatment patterns and survival parameters were characterized and clinical characteristics of the patients were evaluated together with their association with disease progression. <i>Results:</i> 80 stage III/IV patients fulfilling inclusion criteria were identified. Mean age was 62 years and 61% were men. In total, 65% were current smokers and 82% had performance status (ECOG) 0/1. Median progression free survival (mPFS) and median overall survival (mOS) for stage III and IV patients were 8.5 and 5.4 months, and 21.9 and 8.6 months, respectively. The study found that 69% of patients progressed within 9 months from the start of the 1st line treatment. Poor performance status (ECOG 3), male gender, and smoking suggested faster disease progression. Most had received cis/carboplatin-based treatment in the 1st line. Cisplatin regimens were associated with more complete responses and better PFS and OS than the carboplatin ones. <i>Conclusions:</i> By combining algorithmic and manual validation of electronic health care records, clinically valid characteristics and outcomes could be evaluated and presented. This approach forms a basis for tools such as quality registries that can guide treatment decisions. |
| first_indexed | 2024-03-12T06:08:10Z |
| format | Article |
| id | doaj.art-eb5d7df3b4a545418adb8bc1f01839e6 |
| institution | Directory Open Access Journal |
| issn | 1010-660X |
| language | English |
| last_indexed | 2024-03-12T06:08:10Z |
| publishDate | 2019-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj.art-eb5d7df3b4a545418adb8bc1f01839e62023-09-03T03:27:18ZengMDPI AGMedicina1010-660X2019-11-01551174310.3390/medicina55110743medicina55110743Retrospective Evaluation of Lung Adenocarcinoma Patients Progressing on 1st Line ChemotherapyHeikki Vilhonen0Samu Kurki1Tarja Laitinen2Samuli Hirsjärvi3Division of Medicine, Department of Pulmonary Diseases, Turku University Hospital, 20521 Turku, FinlandAuria Biobank, University of Turku, and Turku University Hospital, 20521 Turku, FinlandDivision of Medicine, Department of Pulmonary Diseases, Turku University Hospital, 20521 Turku, FinlandBoehringer Ingelheim Finland Ky, 00180 Helsinki, Finland<i>Background and Objectives:</i> Evaluation of data from electronic health care records could help in guiding towards more rational drug treatments. This single center study evaluated clinical characteristics that could be associated with disease progression. <i>Methods:</i> This was a real world data (RWD) study using existing data from the registries of a university hospital. Patients had lung adenocarcinoma and they had received 1st line treatment. Treatment patterns and survival parameters were characterized and clinical characteristics of the patients were evaluated together with their association with disease progression. <i>Results:</i> 80 stage III/IV patients fulfilling inclusion criteria were identified. Mean age was 62 years and 61% were men. In total, 65% were current smokers and 82% had performance status (ECOG) 0/1. Median progression free survival (mPFS) and median overall survival (mOS) for stage III and IV patients were 8.5 and 5.4 months, and 21.9 and 8.6 months, respectively. The study found that 69% of patients progressed within 9 months from the start of the 1st line treatment. Poor performance status (ECOG 3), male gender, and smoking suggested faster disease progression. Most had received cis/carboplatin-based treatment in the 1st line. Cisplatin regimens were associated with more complete responses and better PFS and OS than the carboplatin ones. <i>Conclusions:</i> By combining algorithmic and manual validation of electronic health care records, clinically valid characteristics and outcomes could be evaluated and presented. This approach forms a basis for tools such as quality registries that can guide treatment decisions.https://www.mdpi.com/1010-660X/55/11/743non-small cell lung canceradenocarcinomachemotherapyreal world data |
| spellingShingle | Heikki Vilhonen Samu Kurki Tarja Laitinen Samuli Hirsjärvi Retrospective Evaluation of Lung Adenocarcinoma Patients Progressing on 1st Line Chemotherapy Medicina non-small cell lung cancer adenocarcinoma chemotherapy real world data |
| title | Retrospective Evaluation of Lung Adenocarcinoma Patients Progressing on 1st Line Chemotherapy |
| title_full | Retrospective Evaluation of Lung Adenocarcinoma Patients Progressing on 1st Line Chemotherapy |
| title_fullStr | Retrospective Evaluation of Lung Adenocarcinoma Patients Progressing on 1st Line Chemotherapy |
| title_full_unstemmed | Retrospective Evaluation of Lung Adenocarcinoma Patients Progressing on 1st Line Chemotherapy |
| title_short | Retrospective Evaluation of Lung Adenocarcinoma Patients Progressing on 1st Line Chemotherapy |
| title_sort | retrospective evaluation of lung adenocarcinoma patients progressing on 1st line chemotherapy |
| topic | non-small cell lung cancer adenocarcinoma chemotherapy real world data |
| url | https://www.mdpi.com/1010-660X/55/11/743 |
| work_keys_str_mv | AT heikkivilhonen retrospectiveevaluationoflungadenocarcinomapatientsprogressingon1stlinechemotherapy AT samukurki retrospectiveevaluationoflungadenocarcinomapatientsprogressingon1stlinechemotherapy AT tarjalaitinen retrospectiveevaluationoflungadenocarcinomapatientsprogressingon1stlinechemotherapy AT samulihirsjarvi retrospectiveevaluationoflungadenocarcinomapatientsprogressingon1stlinechemotherapy |